茶碱作为溶栓辅助治疗急性缺血性卒中:随机安慰剂对照试验
TEA-Stroke 是一项双中心、概念验证的 II 期随机双盲安慰剂对照试验,纳入 MRI 证实的急性缺血性卒中、NIHSS≥4 且 4.5 小时内溶栓的患者,按 1:1 随机接受 220 mg 静脉茶碱或安慰剂。结果显示茶碱组 24 小时 NIHSS 改善 4.7 分,对照组 1.3 分(P=0.044),但梗死体积增长和 90 天功能独立无显著差异,经 Bonferroni 校正后共同主要终点均无显著差异。
要点
- 茶碱辅助溶栓在 24 小时 NIHSS 改善上显示优于安慰剂的信号。
- 梗死体积增长和 90 天功能独立在两组间无显著差异。
- 研究样本量小,尚不能得出茶碱具有神经保护作用的结论。
核心结论
- 茶碱作为溶栓辅助治疗在 24 小时早期临床改善上优于安慰剂,但梗死体积增长和 90 天功能独立无显著差异。
- 经 Bonferroni 多重性校正后,共同主要终点早期临床改善和 24 小时梗死体积增长均无显著差异。
- 研究样本量小,无法就茶碱是否具有神经保护作用得出结论,但提供了支持未来临床试验的积极信号。
研究设计与样本
- TEA-Stroke 试验为研究者发起的双中心、概念验证、II 期临床研究,采用随机双盲安慰剂对照设计。
- 纳入标准为 MRI 证实的急性缺血性卒中、NIHSS≥4 且发病 4.5 小时内接受溶栓治疗。
- 参与者按 1:1 随机接受 220 mg 静脉茶碱或安慰剂。
- 共同主要结局为 24 小时随访时 NIHSS 评分早期临床改善和 MRI 梗死体积增长。
主要发现
- 茶碱组 24 小时 NIHSS 评分平均改善 4.7 分(SD 5.6),对照组改善 1.3 分(SD 7.5),P=0.044。
- 茶碱组平均梗死体积增长 141.6%(SD 126.5),对照组 104.1%(SD 62.5),P=0.146。
- 90 天功能独立率茶碱组为 61%,对照组为 58%,P=0.802。
临床怎么用
- 目前证据尚不支持在溶栓治疗中常规加用茶碱,需等待更大规模临床试验验证。
- 茶碱辅助溶栓的早期神经功能改善信号值得在未来的临床研究中进一步探索。
局限性
- 研究样本量小,无法就茶碱的神经保护作用得出结论。
- 共同主要终点经 Bonferroni 多重性校正后无显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Delayed recanalization increases the risk of infarct growth and poor clinical outcome in acute ischemic stroke. The vasoactive agent theophylline has shown neuroprotective effects in animal stroke models but inconclusive results in case series and randomized clinical trials. The primary objective of this study was to evaluate whether theophylline, as an add-on to thrombolytic therapy, is safe and effective in acute ischemic stroke patients. METHODS: The TEA-Stroke trial (The Theophylline in Acute Ischemic Stroke) was an investigator-initiated 2-center, proof-of-concept, phase II clinical study with a randomized, double-blinded, placebo-controlled design. The main inclusion criteria were magnetic resonance imaging-verified acute ischemic stroke, moderate to severe neurological deficit (National Institutes of Health Stroke Scale score of ≥4), and treatment with thrombolysis within 4.5 hours of onset. Participants were randomly assigned in the ratio 1:1 to either 220 mg of intravenous theophylline or placebo. The co-primary outcomes were early clinical improvement on the National Institutes of Health Stroke Scale score and infarct growth on magnetic resonance imaging at 24-hour follow-up. RESULTS: Theophylline as an add-on to thrombolytic therapy improved the National Institutes of Health Stroke Scale score at 24 hours by mean 4.7 points (SD, 5.6) compared with an improvement of 1.3 points (SD, 7.5) in the control group (P=0.044). Mean infarct growth was 141.6% (SD, 126.5) and 104.1% (SD, 62.5) in the theophylline and control groups, respectively (P=0.146). Functional independence at 90 days was 61% in the theophylline group and 58% in the control group (P=0.802). CONCLUSIONS: This proof-of-concept trial investigated theophylline administration as an add-on to thrombolytic therapy in acute ischemic stroke. The co-primary end points early clinical improvement and infarct growth at 24-hour follow-up were not significantly different after post hoc correction for multiplicity (Bonferroni technique). The small study size precludes a conclusion as to whether theophylline has a neuroprotective effect but provides a promising clinical signal that may support a future clinical trial. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: EudraCT number 2013-001989-42.
引用
- Modrau B, Andersen G, Mikkelsen IK, et al. Theophylline as an Add-On to Thrombolytic Therapy in Acute Ischemic Stroke: A Randomized Placebo-Controlled Trial. Stroke. 2020. PMID: 32568651. doi:10.1161/STROKEAHA.119.027446
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。